Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LONDON AND NEW YORK, DEC. 19, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, ANNOUNCED THAT EXECUTIVE CHAIRMAN AND FOUNDER, GABRIELE CERRONE AND THE OKYO MANAGEMENT TEAM WILL RING THE OPENING BELL AT THE NASDAQ MARKETSITE IN TIMES SQUARE, NEW YORK TODAY.

OKYO PHARMA TO RING THE OPENING BELL AT NASDAQ

LONDON AND NEW YORK, DEC. 15, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, TODAY ANNOUNCES IT HAS BEEN INFORMED THAT PANETTA PARTNERS LIMITED, AN ENTITY IN WHICH GABRIELE CERRONE, THE EXECUTIVE CHAIRMAN, HAS A BENEFICIAL INTEREST, HAS ACQUIRED 24,551 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ, BRINGING HIS TOTAL HOLDING TO 10,516,297 SHARES.

OKYO PHARMA ANNOUNCES CHAIRMAN AND FOUNDER ACQUIRES SHARES

LONDON AND NEW YORK, NOV. 21, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, TODAY ANNOUNCES THAT PANETTA PARTNERS LIMITED, AN ENTITY IN WHICH GABRIELE CERRONE, EXECUTIVE CHAIRMAN HAS A BENEFICIAL INTEREST, HAS ACQUIRED 82,018 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ, BRINGING HIS TOTAL HOLDING TO 10,464,695 SHARES.

LONDON AND NEW YORK, NOV. 18, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, ANNOUNCED THAT GARY S. JACOB, PH.D., CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE OPHTHALMOLOGY INNOVATION SUMMIT (OIS) XV. THE PRESENTATION IS SCHEDULED FOR SATURDAY, NOVEMBER 22, 2025, FROM 8:30-9:30 AM PT, AS PART OF THE "ANTERIOR INNOVATION SHOWCASE" SESSION.

OKYO PHARMA TO PRESENT AT OIS XV IN SAN DIEGO

LONDON AND NEW YORK, OCT. 16, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, TODAY ANNOUNCES IT HAS BEEN INFORMED THAT PANETTA PARTNERS LIMITED, AN ENTITY IN WHICH GABRIELE CERRONE, THE EXECUTIVE CHAIRMAN HAS A BENEFICIAL INTEREST, HAS ACQUIRED 210,000 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ, BRINGING HIS TOTAL HOLDING TO 10,382,677 SHARES.

LONDON AND NEW YORK, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, TODAY ANNOUNCED PLANS FOR THE NEXT STAGE OF CLINICAL DEVELOPMENT FOR ITS LEAD DRUG CANDIDATE, URCOSIMOD, TO TREAT NEUROPATHIC CORNEAL PAIN (NCP).

OKYO PHARMA ANNOUNCES REGISTRATION PATHWAY WITH 100 PATIENT MULTI-CENTER CLINICAL TRIAL OF URCOSIMOD IN NEUROPATHIC CORNEAL PAIN

LONDON AND NEW YORK, JULY 16, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN (NCP), AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE NERVE-RELATED PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, IS PLEASED TO ANNOUNCE POSITIVE TOP-LINE DATA FROM THE RECENTLY CLOSED 18-PATIENT PHASE 2 TRIAL OF URCOSIMOD (FORMERLY CALLED OK-101) TO TREAT NCP. OKYO IS THE FIRST COMPANY TO CONDUCT A CLINICAL STUDY TO TREAT NCP DISEASE, A MAJOR UNMET MEDICAL NEED.

OKYO PHARMA UNVEILS STRONG PHASE 2 CLINICAL TRIAL RESULTS FOR URCOSIMOD TO TREAT NEUROPATHIC CORNEAL PAIN

RAISING PRICE TARGET DUE TO FUNDAMENTAL DRIVERS BALTIMORE, MD / ACCESS NEWSWIRE / JUNE 11, 2025 / GOLDMAN SMALL CAP RESEARCH, A STOCK MARKET RESEARCH FIRM SPECIALIZING IN THE SMALL CAP AND MICROCAP SECTORS, ANNOUNCED TODAY THAT IT HAS PUBLISHED A NEW RESEARCH UPDATE ON OKYO PHARMA LIMITED (NASDAQ:OKYO), AN EMERGING PLAYER IN THE FAST-GROWING OPHTHALMIC DRUGS SEGMENT. THE GOLDMAN REPORT CARRIES A PRICE TARGET.

GOLDMAN SMALL CAP RESEARCH ISSUES NEW RESEARCH UPDATE ON OKYO PHARMA LIMITED

LONDON AND NEW YORK, MAY 19, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN, A SEVERE OCULAR CONDITION WITHOUT AN FDA APPROVED THERAPY, AND FOR INFLAMMATORY EYE DISEASES, ANNOUNCED THAT ITS CEO, GARY S. JACOB, PH.D., WILL BE GIVING AN ORAL PRESENTATION AT THE 4TH ANNUAL GPCRS-TARGETED DRUG DISCOVERY SUMMIT IN BOSTON, MA ON MAY 22, 2025. DR. JACOB'S PRESENTATION WILL COVER THE DEVELOPMENT OF URCOSIMOD, OKYO'S LEAD CLINICAL DRUG CANDIDATE, TO TREAT NEUROPATHIC CORNEAL PAIN (NCP) WHICH IS A DEBILITATING CONDITION AFFECTING MANY TENS OF THOUSANDS WORLDWIDE, AND IS CHARACTERIZED BY CHRONIC, SEVERE EYE DISCOMFORT.

OKYO PHARMA TO PRESENT AT THE GPCRS-TARGETED DRUG DISCOVERY SUMMIT

LONDON AND NEW YORK, APRIL 30, 2025 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), AN OPHTHALMOLOGY-FOCUSED BIO-PHARMACEUTICAL COMPANY WHICH IS DEVELOPING URCOSIMOD (FORMERLY CALLED OK-101) TO TREAT NCP, AN OCULAR CONDITION ASSOCIATED WITH CHRONIC AND OFTEN SEVERE PAIN BUT WITHOUT AN FDA-APPROVED THERAPY, ANNOUNCES PLANS TO ACCELERATE THE CLINICAL DEVELOPMENT OF URCOSIMOD TO TREAT NCP THROUGH THE ANALYSIS OF ITS DATA FOLLOWING THE EARLY CLOSURE OF ITS PHASE 2 TRIAL.

OKYO Pharma Limited

OKYO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OKYO Pharma Limited

OKYO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OKYO